These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 23235192)
21. [Somatostatin receptor scintigraphy (SRS) in a neuroendocrine pancreatic tumor: why SPECT?]. Lang O; Bihl H Nuklearmedizin; 2000; 39(4):N55-7. PubMed ID: 10919167 [No Abstract] [Full Text] [Related]
22. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
23. PET imaging in neuroendocrine tumors: current status and future prospects. Basu S; Kumar R; Rubello D; Fanti S; Alavi A Minerva Endocrinol; 2008 Sep; 33(3):257-75. PubMed ID: 18846029 [TBL] [Abstract][Full Text] [Related]
24. [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms]. Hommann M; Kaemmerer D; Hörsch D; Kulkarni HR; Robiller F; Baum RP Chirurg; 2014 Jun; 85(6):500-4. PubMed ID: 24844432 [TBL] [Abstract][Full Text] [Related]
25. Nuclear medicine in NET. Sorschag M; Malle P; Gallowitsch HJ Wien Med Wochenschr; 2012 Oct; 162(19-20):416-22. PubMed ID: 22810487 [TBL] [Abstract][Full Text] [Related]
26. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
27. Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours. Lopci E; Nanni C; Rampin L; Rubello D; Fanti S Minerva Endocrinol; 2008 Sep; 33(3):277-81. PubMed ID: 18846030 [TBL] [Abstract][Full Text] [Related]
28. [Imaging techniques in the diagnosis of neuroendocrine tumors]. Díez JJ; Iglesias P Med Clin (Barc); 2010 Sep; 135(7):319-25. PubMed ID: 19595379 [TBL] [Abstract][Full Text] [Related]
29. Functional imaging of neuroendocrine tumours with PET. Mottaghy FM; Reske SN Pituitary; 2006; 9(3):237-42. PubMed ID: 17036194 [TBL] [Abstract][Full Text] [Related]
30. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600 [TBL] [Abstract][Full Text] [Related]
31. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. Hofman MS; Kong G; Neels OC; Eu P; Hong E; Hicks RJ J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744 [TBL] [Abstract][Full Text] [Related]
32. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441 [TBL] [Abstract][Full Text] [Related]
33. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Warner RR; O'dorisio TM Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602 [TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942 [TBL] [Abstract][Full Text] [Related]
35. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms. Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148 [TBL] [Abstract][Full Text] [Related]
36. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours. Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344 [TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Hofman MS; Lau WF; Hicks RJ Radiographics; 2015; 35(2):500-16. PubMed ID: 25763733 [TBL] [Abstract][Full Text] [Related]
38. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Sharma P; Arora S; Dhull VS; Naswa N; Kumar R; Ammini AC; Bal C Abdom Imaging; 2015 Feb; 40(2):299-309. PubMed ID: 25134801 [TBL] [Abstract][Full Text] [Related]
40. Contemporary nuclear medicine imaging of neuroendocrine tumours. Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]